Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
MarketBeat

Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%

Caris Life Sciences (NASDAQ:CAI) executives said the company is expanding its commercial reach, product pipeline and biopharma partnerships as it looks to build on recent revenue growth following its IPO last June.

Speaking at an investor conference, a Caris executive identified by Chief Scientific Officer Milan Radovich as Brian said the company sees “more remarkable” market opportunities for its precision oncology platform than at any point since its founding in 2008. He said Caris is annualizing at more than 200,000 molecular profiles and reaches more than 6,100 oncologists in the U.S.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.